AFFX Affymetrix, Inc.

Affymetrix Inc. (Nasdaq:AFFX) and Zhejiang California Nanosystem Institute (ZCNI) at Zhejiang University announced today that they have entered into a collaboration to develop clinical applications using GeneChip(R) technology. This is Affymetrix' first translational medicine collaboration in China. Under terms of the agreement, ZCNI researchers will use Affymetrix GeneChip microarray technology for translational medicine research projects, beginning with cancer, newborn genetic diseases and infectious diseases. In addition, the two organizations are establishing a joint laboratory that will support clinical researchers at Zhejiang University and its six affiliated hospitals. The researchers will use Affymetrix GeneChip technology to analyze genomic information across large patient samples. The data will enable them to more rapidly discover RNA and DNA patterns that can better classify, manage and treat clinically important diseases. "We are excited about using the Affymetrix GeneChip technology to explore the relationship between genes and human health and to develop clinical applications to improve healthcare in China," said Professor Jiaan Cheng, director of ZCNI and former vice president of Research at Zhejiang University. "This collaboration will enable us to develop a more personalized form of medicine, which should help improve healthcare in China and around the world." "As an alumnus and a former faculty member of this distinguished University, I am very impressed by the cutting-edge research that is taking place at the ZCNI and the School of Medicine," said Wei Zhou, Ph.D. vice president, Intellectual Property and Advanced Technology and China Country Manager at Affymetrix. "With this translational medicine strategic partnership and the joint laboratory, we hope to accelerate clinical research and bring better healthcare to patients." Affymetrix collaborates with academic institutions, advocacy groups and the pharmaceutical and diagnostics community through its Translational Medicine Program to develop molecular signatures for improving patient care. Affymetrix GeneChip microarray technology helps researchers to diagnose and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. The Translational Medicine Program complements the Powered by Affymetrix(TM) program, which enables companies to license GeneChip technology to create innovative, custom-designed microarray products based on signatures such as those of our translational medicine partners. This technology is already being used in many applications, including diagnostics, forensics, animal, industrial and food testing. About Zhejiang University Zhejiang University is one of the top universities in China. The main campus is located near picturesque West Lake, a famous tourist location. Zhejiang University officially combined with Hangzhou University, Zhejiang Agriculture University and Zhejiang Medical University (all located in the city of Hangzhou) in the summer of 1998. The combined university is called Zhejiang University, which is one of the largest in China. Presently, 41,000 students attend the university, including more than 24,000 undergraduates, 11,000 postgraduates working for master's degrees and 6,000 Ph.D. candidates. More information about Zhejiang University can be found at http://www.zju.edu.cn/. About Zhejiang California Nanosystem Institute (ZCNI) Zhejiang California International Nanosystem Institute (ZCNI) is a research and technology innovation platform in China established on June, 2005. It is a joint effort among Zhejiang Provincial Government, Zhejiang University (ZJU), California NanoSystems Institute (CNSI). The mission of the Institute is to accelerate the application of nanotechnology in systems biology, medicine, material, information technology, chemistry etc. ZCNI strives to become the catalyst of the integration of academics and industry, the accelerator of the development of Zhejiang science and technology and the new engine of the evolution of Zhejiang society and economy. About Affymetrix Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and more than 7,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the outcome of the collaboration with the Zhejiang California Nanosystem Institute discussed in this press release; risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses; uncertainties relating to technological approaches, manufacturing, product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K/A for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc.